Zobrazeno 1 - 10 of 1 077 pro vyhledávání: '"Davenport AJ"'
1
Akademický článek
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses.
Autor: Lertsumitkul L; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia., Iliopoulos M; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Wang SS; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia., McArthur SJ; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Ebert LM; Translational Oncology, Centre for Cancer Biology, Adelaide, South Australia, Australia.; The University of Adelaide Adelaide Medical School, Adelaide, South Australia, Australia.; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia., Davenport AJ; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Endersby R; Brain Tumour Research Program, Telethon Kids Institute, Perth, Western Australia, Australia., Hansford JR; Michael Rice Children's Hematology and Oncology Center, Women's and Children's Hospital; South Australia Health and Medical Research Institute; South Australia ImmmunoGenomics Cancer Institute, University of Adelaide, Adelaide, South Australia, Australia., Drummond KJ; Department of Neurosurgery, Royal Melbourne Hospital Department of Surgery, Parkville, Victoria, Australia.; Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia., Cross R; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Jenkins MR; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia jenkins.m@wehi.edu.au.; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.; Department of Biochemistry and Chemistry, La Trobe University, Melbourne, Victoria, Australia.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Aug 07; Vol. 12 (8). Date of Electronic Publication: 2024 Aug 07.
Zobrazit plný text záznamu
2
Akademický článek
Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor.
Autor: Langer G; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.) stefan.baeurle@bayer.com gernot.langer@bayer.com., Scott J; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Lind C; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Otto C; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Bothe U; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Laux-Biehlmann A; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Müller J; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., le Roy B; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Irlbacher H; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Nowak-Reppel K; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Schlüter A; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Davenport AJ; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Slack M; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)., Bäurle S; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.) stefan.baeurle@bayer.com gernot.langer@bayer.com.
Publikováno v: Molecular pharmacology [Mol Pharmacol] 2023 Sep; Vol. 104 (3), pp. 105-114. Date of Electronic Publication: 2023 Jun 22.
Zobrazit plný text záznamu
3
Akademický článek
A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma.
Autor: Pandey K; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia., Wang SS; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Children's Cancer Centre, Royal Children's Hospital, Parkville, VIC, Australia., Mifsud NA; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia., Faridi P; Monash Proteomics and Metabolomics Facility, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.; School of Clinical Sciences, Department of Medicine, Monash University, Clayton, VIC, Australia.; Department of Medicine, Sub-Faculty of Clinical and Molecular Medicine, Faculty of Medicine, Nursing & Health Sciences, Monash University, Clayton, VIC, Australia.; Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.; Department of Molecular and Translational Medicine, School of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia., Davenport AJ; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Webb AI; Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Sandow JJ; Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Ayala R; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia., Monje M; Department of Neurology and Neurological Sciences and Howard Hughes Medical Institute, Stanford University, Stanford, CA, United States., Cross RS; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Ramarathinam SH; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia., Jenkins MR; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; The Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.; LaTrobe Institute for Molecular Science, LaTrobe University, Bundoora, VIC, Australia., Purcell AW; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Publikováno v: Frontiers in oncology [Front Oncol] 2023 Aug 11; Vol. 13, pp. 1192448. Date of Electronic Publication: 2023 Aug 11 (Print Publication: 2023).
Zobrazit plný text záznamu
4
Akademický článek
HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
Autor: Wang SS; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Murdoch Children's Research Institute, Parkville, VIC, Australia.; Children's Cancer Centre, Royal Children's Hospital, Parkville, VIC, Australia., Davenport AJ; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Iliopoulos M; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Hughes-Parry HE; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Watson KA; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Arcucci V; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Mulazzani M; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Eisenstat DD; Murdoch Children's Research Institute, Parkville, VIC, Australia.; Children's Cancer Centre, Royal Children's Hospital, Parkville, VIC, Australia., Hansford JR; Michael Rice Cancer Centre, Women's and Children's Hospital, South Australia Health and Medical Research Institute, South Australia ImmunoGENomics Cancer Institute, University of Adelaide, Adelaide, South Australia, Australia., Cross RS; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Jenkins MR; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, Australia.; Department of Biochemistry, La Trobe Institute for Molecular Science, Bundoora, VICAustralia.
Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2023 May 04; Vol. 5 (1), pp. vdad024. Date of Electronic Publication: 2023 May 04 (Print Publication: 2023).
Zobrazit plný text záznamu
5
Akademický článek
Super-killer CTLs are generated by single gene deletion of Bach2.
Autor: Barton PR; Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK., Davenport AJ; Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK., Hukelmann J; Cell Signalling and Immunology Division, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK., Cantrell DA; Cell Signalling and Immunology Division, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK., Stinchcombe JC; Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK., Richard AC; Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0RE, UK., Griffiths GM; Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK.
Publikováno v: European journal of immunology [Eur J Immunol] 2022 Nov; Vol. 52 (11), pp. 1776-1788. Date of Electronic Publication: 2022 Sep 26.
Zobrazit plný text záznamu
6
Akademický článek
Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers.
Autor: Davenport AJ; Discovery Chemistry, Dorothy Crowfoot Hodgkin Campus, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK., Neagoe I; In Vitro Pharmacology, Manfred Eigen Campus, Evotec SE, Essener Bogen 7, 22419, Hamburg, Germany.; Research, In Vitro Biology, Galapagos, Generaal De Wittelaan L11 A3,, 2800, Mechlin, Belgium., Bräuer N; Pharmaceuticals Division, Drug Discovery, Candidate Generation & Exploration, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353, Berlin, Germany.; Life Sciences Chemistry, Nuvisan ICB GmbH, Müllerstr. 178, 13353, Berlin, Germany., Koch M; Pharmaceuticals Division, Research and Development, Preclinical Research, Therapeutic Area Endocrinology, Metabolism and Reproductive Health, Bayer AG, Müllerstr. 178, 13353, Berlin, Germany., Rotgeri A; Pharmaceuticals Division, Drug Discovery, Early Development, Drug Metabolism and Pharmacokinetics, Bayer AG, Müllerstr. 178, 13353, Berlin, Germany.; Preclinical Compound Profiling, Nuvisan ICB GmbH, Müllerstr. 178, 13353, Berlin, Germany., Nagel J; Pharmaceuticals Division, Research and Development, Preclinical Research, Therapeutic Area Endocrinology, Metabolism and Reproductive Health, Bayer AG, Müllerstr. 178, 13353, Berlin, Germany., Laux-Biehlmann A; Research & Development, Pulmonary Drug Discovery Laboratory, Bayer US LLC, Boston, MA, USA., Machet F; In Vivo Pharmacology, Campus Curie, Evotec SAS, 195 route d'Espagne, 31036, Toulouse, France., Coelho AM; In Vivo Pharmacology, Manfred Eigen Campus, Evotec SE, Essener Bogen 7, 22419, Hamburg, Germany., Boyce S; In Vivo Pharmacology, Manfred Eigen Campus, Evotec SE, Essener Bogen 7, 22419, Hamburg, Germany., Carty N; In Vitro Pharmacology, Manfred Eigen Campus, Evotec SE, Essener Bogen 7, 22419, Hamburg, Germany., Gemkow MJ; Neurosciences, Manfred Eigen Campus, Evotec SE, Essener Bogen 7, 22419, Hamburg, Germany., Hess SD; In Vitro Pharmacology, Manfred Eigen Campus, Evotec SE, Essener Bogen 7, 22419, Hamburg, Germany., Zollner TM; Pharmaceuticals Division, Research and Development, Preclinical Research, Therapeutic Area Endocrinology, Metabolism and Reproductive Health, Bayer AG, Müllerstr. 178, 13353, Berlin, Germany., Fischer OM; Pharmaceuticals Division, Research and Development, Preclinical Research, Therapeutic Area Endocrinology, Metabolism and Reproductive Health, Bayer AG, Müllerstr. 178, 13353, Berlin, Germany. oliver-martin.fischer@bayer.com.
Publikováno v: Scientific reports [Sci Rep] 2021 Oct 06; Vol. 11 (1), pp. 19877. Date of Electronic Publication: 2021 Oct 06.
Zobrazit plný text záznamu
7
Akademický článek
Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti‐tumour activity.
Autor: Wang, Yao1,2,3,4 (AUTHOR), Li, Jianhuan1,2,3,4 (AUTHOR), Wang, Zhiqian2,3,4 (AUTHOR), Liu, Yanhong2 (AUTHOR), Wang, Tongjie2 (AUTHOR), Zhang, Mengyun2 (AUTHOR), Xia, Chengxiang3 (AUTHOR), Zhang, Fan2,3,4 (AUTHOR), Huang, Dehao2 (AUTHOR), Zhang, Leqiang3 (AUTHOR), Zhao, Yaoqin2,3,5 (AUTHOR), Liu, Lijuan2 (AUTHOR), Zhu, Yanping2 (AUTHOR), Qi, Hanmeng3 (AUTHOR), Zhu, Xiaofan6,7 (AUTHOR), Qian, Wenbin8 (AUTHOR), Hu, Fangxiao3 (AUTHOR) hufangxiao@biscrm.ac.cn, Wang, Jinyong2,3,4 (AUTHOR) wangjinyong@ioz.ac.cn
Publikováno v: Cell Proliferation. Nov2024, Vol. 57 Issue 11, p1-14. 14p.
Zobrazit plný text záznamu
8
Akademický článek
Scalable Ir-Doped NiFe2O4/TiO2 Heterojunction Anode for Decentralized Saline Wastewater Treatment and H2 Production.
Autor: Hong, Sukhwa1 (AUTHOR), Kim, Jiseon1 (AUTHOR), Park, Jaebeom1 (AUTHOR), Im, Sunmi1 (AUTHOR), Hoffmann, Michael R.2 (AUTHOR), Cho, Kangwoo1,2,3 (AUTHOR) kwcho1982@postech.ac.kr
Publikováno v: Nano-Micro Letters. 10/28/2024, Vol. 17 Issue 1, p1-18. 18p.
Zobrazit plný text záznamu
9
Akademický článek
Evaluation of Anti-inflammatory and Antioxidant Properties of Persea Americana and Syzygium Aromaticum-based Herbal Mouthwash Formulation: An In-vitro Study.
Autor: DHARINI, S.1, PANDIAR, DEEPAK2 deepakpandiar1923@yahoo.com, RAJESHKUMAR, S.3, KRISHNAN, RESHMA POOTHAKULATH4
Publikováno v: Journal of Clinical & Diagnostic Research. Oct2024, Vol. 18 Issue 10, p1-5. 5p.
Zobrazit plný text záznamu
10
Akademický článek
Insight into antibacterial effect of titanium nanotubular surfaces with focus on Staphylococcus aureus and Pseudomonas aeruginosa.
Autor: Šístková, Jana1 (AUTHOR), Fialová, Tatiana2 (AUTHOR), Svoboda, Emil3 (AUTHOR), Varmužová, Kateřina1 (AUTHOR), Uher, Martin1 (AUTHOR), Číhalová, Kristýna2 (AUTHOR), Přibyl, Jan4 (AUTHOR), Dlouhý, Antonín5 (AUTHOR), Pávková Goldbergová, Monika1 (AUTHOR) goldberg@med.muni.cz
Publikováno v: Scientific Reports. 7/27/2024, Vol. 14 Issue 1, p1-20. 20p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje